JP2002502370A - 脳血管障害の処置に有用な薬剤の調製のための1,2,4−トリアゾロ[1,5−c]ピリミジン複素環アナログの使用 - Google Patents

脳血管障害の処置に有用な薬剤の調製のための1,2,4−トリアゾロ[1,5−c]ピリミジン複素環アナログの使用

Info

Publication number
JP2002502370A
JP2002502370A JP54991798A JP54991798A JP2002502370A JP 2002502370 A JP2002502370 A JP 2002502370A JP 54991798 A JP54991798 A JP 54991798A JP 54991798 A JP54991798 A JP 54991798A JP 2002502370 A JP2002502370 A JP 2002502370A
Authority
JP
Japan
Prior art keywords
group
formula
alkyl
alkoxy
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP54991798A
Other languages
English (en)
Japanese (ja)
Inventor
オンギニ,エンニオ
アダミ,マリナ
ベルトレリ,ロザリア
Original Assignee
シェーリング−プラウ エセ.ピー.アー.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by シェーリング−プラウ エセ.ピー.アー. filed Critical シェーリング−プラウ エセ.ピー.アー.
Publication of JP2002502370A publication Critical patent/JP2002502370A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP54991798A 1997-05-21 1998-05-14 脳血管障害の処置に有用な薬剤の調製のための1,2,4−トリアゾロ[1,5−c]ピリミジン複素環アナログの使用 Pending JP2002502370A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IT97MI001190A IT1291372B1 (it) 1997-05-21 1997-05-21 Uso di analoghi eterociclici di 1,2,4-triazolo (1,5-c) pirimidine per la preparazione di medicamenti utili per il trattamento delle malattie
IT97A001190 1997-05-21
PCT/EP1998/002852 WO1998052568A1 (en) 1997-05-21 1998-05-14 THE USE OF 1,2,4-TRIAZOLO[1,5-c]PYRIMIDINE HETEROCYCLIC ANALOGUES FOR THE PREPARATION OF MEDICAMENTS USEFUL FOR THE TREATMENT OF CEREBROVASCULAR DISTURBANCES

Publications (1)

Publication Number Publication Date
JP2002502370A true JP2002502370A (ja) 2002-01-22

Family

ID=11377184

Family Applications (1)

Application Number Title Priority Date Filing Date
JP54991798A Pending JP2002502370A (ja) 1997-05-21 1998-05-14 脳血管障害の処置に有用な薬剤の調製のための1,2,4−トリアゾロ[1,5−c]ピリミジン複素環アナログの使用

Country Status (9)

Country Link
EP (1) EP0983068B1 (cg-RX-API-DMAC7.html)
JP (1) JP2002502370A (cg-RX-API-DMAC7.html)
CN (1) CN1255854A (cg-RX-API-DMAC7.html)
AT (1) ATE209492T1 (cg-RX-API-DMAC7.html)
AU (1) AU740475B2 (cg-RX-API-DMAC7.html)
CA (1) CA2289847A1 (cg-RX-API-DMAC7.html)
DE (1) DE69802679D1 (cg-RX-API-DMAC7.html)
IT (1) IT1291372B1 (cg-RX-API-DMAC7.html)
WO (1) WO1998052568A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006219497A (ja) * 2000-05-26 2006-08-24 Schering Plough Corp アデノシンa2aレセプターアンタゴニスト

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0100624D0 (en) * 2001-01-10 2001-02-21 Vernalis Res Ltd Chemical compounds VII
EP1575916B1 (en) 2001-08-31 2013-05-22 The Rockefeller University Phosphodiesterase activity and regulation of phosphodiesterase 1-b-mediated signaling in brain
EP1430898A4 (en) * 2001-09-28 2005-11-02 Kyowa Hakko Kogyo Kk Receptor antagonist
JP4545437B2 (ja) 2001-10-15 2010-09-15 シェーリング コーポレイション アデノシンa2a受容体アンタゴニストとしてのイミダゾ(4,3−e)−1,2,4−トリアゾロ(1,5−c)ピリミジン
CA2468658C (en) 2001-11-30 2009-04-14 Schering Corporation [1,2,4]-triazole bicyclic adenosine a2a receptor antagonists
TW200300686A (en) 2001-11-30 2003-06-16 Schering Corp Adenosine A2a receptor antagonists
AU2002346503A1 (en) 2001-11-30 2003-06-17 Schering Corporation Adenosine A2a receptor antagonists
EP1622912B1 (en) 2003-04-23 2009-05-27 Schering Corporation 2-alkynyl-and 2-alkenyl-pyrazolo- [4,3-e ] -1,2,4-triazolo- [1,5-c] -pyrimidine adenosine a2a receptor antagonists
ATE461932T1 (de) 2004-04-21 2010-04-15 Schering Corp Pyrazoloä4,3-eü-1,2,4-triazoloä1,5-cüpyrimidine als antagonisten des adenosin-a2a-rezeptors
WO2006133261A2 (en) 2005-06-06 2006-12-14 Intra-Cellular Therapies, Inc. Organic compounds
AR057817A1 (es) 2005-09-19 2007-12-19 Schering Corp Antagonistas del receptor a2a de 2-heteroaril-pirazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pirimidin adenosina. composiciones farmaceuticas
AR056080A1 (es) 2005-09-23 2007-09-19 Schering Corp 7-[2-[4-(6-fluoro-3-metil-1,2-benciosoxazol-5-il)-1-piperazinil]etil]-2-(1-propinil)-7h-pirazol-[4,3-e]-[1,2,4]-triazol-[1,5-c] -pirimidin-5-amine
ES2273599B1 (es) 2005-10-14 2008-06-01 Universidad De Barcelona Compuestos para el tratamiento de la fibrilacion auricular.
AU2007256633B2 (en) 2006-06-06 2013-09-12 Intra-Cellular Therapies, Inc. Organic compounds
WO2008063505A1 (en) 2006-11-13 2008-05-29 Intra-Cellular Therapies, Inc. Organic compounds
WO2008070095A1 (en) 2006-12-05 2008-06-12 Intra-Cellular Therapies, Inc. Novel uses
US7691869B2 (en) 2007-03-30 2010-04-06 King Pharmaceuticals Research And Development, Inc. Pyrrolotriazolopyrimidine derivatives, pharmaceutical compositions containing them and methods of treating conditions and diseases mediated by the adenosine A2A receptor activity
ES2588238T3 (es) 2007-12-06 2016-10-31 Intra-Cellular Therapies, Inc. Derivados de pirazolopirimidin-4,6-diona y su uso como producto farmacéutico
EP2939676A1 (en) 2007-12-06 2015-11-04 Intra-Cellular Therapies, Inc. Organic compounds
JP2011513417A (ja) 2008-03-04 2011-04-28 シェーリング コーポレイション アデノシンA2a受容体アンタゴニストとして使用するための1,2,4−トリアゾロ[4,3−c]ピリミジン−3−オンおよびピラゾロ[4,3−e]−1,2,4−トリアゾロ[4,3−c]ピリミジン−3−オン化合物
US20110190324A1 (en) * 2008-07-16 2011-08-04 Edward Leung Methods of treating atherosclerosis
BRPI0922700A2 (pt) 2008-12-06 2015-08-11 Intracellular Therapies Inc Compostos orgânicos
EA201170769A1 (ru) 2008-12-06 2012-02-28 Интра-Селлулар Терапиз, Инк. Органические соединения
PE20110922A1 (es) 2008-12-06 2012-01-22 Intra Cellular Therapies Inc DERIVADOS DE PIRAZOLO[4,3-e]PIRIMIDIN COMO INHIBIDORES DE LA FOSFODIESTERASA 1 (PDE1)
AU2009322903A1 (en) 2008-12-06 2010-06-10 Intra-Cellular Therapies, Inc. Organic compounds
AU2009322899A1 (en) 2008-12-06 2010-06-10 Intra-Cellular Therapies, Inc. Organic compounds
MX2011005934A (es) 2008-12-06 2011-12-16 Intra Cellular Therapies Inc Compuestos organicos.
WO2010098839A1 (en) 2009-02-25 2010-09-02 Intra-Cellular Therapies, Inc. Pde 1 inhibitors for ophthalmic disorders
EP2434895A4 (en) 2009-05-13 2013-08-07 Intra Cellular Therapies Inc ORGANIC CONNECTIONS
WO2011016861A2 (en) 2009-08-05 2011-02-10 Intra-Cellular Therapies, Inc. Novel regulatory proteins and inhibitors
US9763948B2 (en) 2010-05-31 2017-09-19 Intra-Cellular Therapies, Inc. PDE1 inhibitory compounds and methods
EP2575817A4 (en) 2010-05-31 2014-01-08 Intra Cellular Therapies Inc ORGANIC CONNECTIONS
TW201206937A (en) 2010-05-31 2012-02-16 Intra Cellular Therapies Inc Organic compounds
US9371327B2 (en) 2010-05-31 2016-06-21 Intra-Cellular Therapies, Inc. PDE1 inhibitor compounds
EP2717877B1 (en) 2011-06-10 2017-11-08 Intra-Cellular Therapies, Inc. Organic compounds
WO2014101120A1 (en) 2012-12-28 2014-07-03 Merck Sharp & Dohme Corp. Heterobicyclo-substituted-7-methoxy-[1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds with a2a antagonist properties
EP2956141A4 (en) 2013-02-17 2016-10-26 Intra Cellular Therapies Inc NEW USES
DK2970279T3 (da) 2013-03-15 2020-11-30 Intra Cellular Therapies Inc Organiske forbindelser
ES2717688T3 (es) 2013-03-15 2019-06-24 Intra Cellular Therapies Inc Inhibidores de la PDE1 para uso en el tratamiento y/o prevención de lesiones de SNC, y enfermedades, trastornos o lesiones de SNP
JP6696904B2 (ja) 2014-01-08 2020-05-20 イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. 製剤および医薬組成物
DK3157926T3 (da) 2014-06-20 2019-08-19 Intra Cellular Therapies Inc Organiske forbindelser
US10131671B2 (en) 2014-08-07 2018-11-20 Intra-Cellular Therapies, Inc. Organic compounds
US10285992B2 (en) 2014-08-07 2019-05-14 Intra-Cellular Therapies, Inc. Combinations of PDE1 inhibitors and NEP inhibitors and associated methods
US9546175B2 (en) 2014-08-07 2017-01-17 Intra-Cellular Therapies, Inc. Organic compounds
CA2961212C (en) 2014-09-17 2024-02-06 Intra-Cellular Therapies, Inc. Compounds and methods
AU2015350315B2 (en) 2014-11-18 2020-06-25 Merck Sharp & Dohme Corp. Aminopyrazine compounds with A2A antagonist properties
BR112017012007B1 (pt) 2014-12-06 2022-11-01 Intra-Cellular Therapies, Inc Compostos orgânicos inibitórios de pde2, composições farmacêuticas compreendendo os ditos compostos e uso dos mesmos no tratamento de um distúrbio mediado por pde2
WO2016090382A1 (en) 2014-12-06 2016-06-09 Intra-Cellular Therapies, Inc. Organic compounds
WO2016126570A1 (en) 2015-02-06 2016-08-11 Merck Sharp & Dohme Corp. Aminoquinazoline compounds as a2a antagonist
EP3307067B1 (en) 2015-06-11 2022-11-02 Merck Sharp & Dohme LLC Aminopyrazine compounds with a2a antagonist properties
WO2017008205A1 (en) 2015-07-10 2017-01-19 Merck Sharp & Dohme Corp. Substituted aminoquinazoline compounds as a2a antagonist
US10682354B2 (en) 2016-03-28 2020-06-16 Intra-Cellular Therapies, Inc. Compositions and methods
US11291666B2 (en) 2016-09-12 2022-04-05 Intra-Cellular Therapies, Inc. Uses
US11498923B2 (en) 2017-12-13 2022-11-15 Merck Sharp & Dohme Llc Substituted imidazo[1,2-c]quinazolines as A2A antagonists
JP7401442B2 (ja) 2018-01-31 2023-12-19 イントラ-セルラー・セラピーズ・インコーポレイテッド 新規使用
US12410175B2 (en) 2019-09-03 2025-09-09 Intra-Cellular Therapies, Inc. Compounds
CN111072676B (zh) * 2019-12-12 2021-07-16 广东东阳光药业有限公司 含氮稠合三环衍生物及其用途
US12364695B2 (en) 2020-06-02 2025-07-22 Intra-Cellular Therapies, Inc. Methods of treating inflammatory disease

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006219497A (ja) * 2000-05-26 2006-08-24 Schering Plough Corp アデノシンa2aレセプターアンタゴニスト

Also Published As

Publication number Publication date
ITMI971190A0 (cg-RX-API-DMAC7.html) 1997-05-21
AU740475B2 (en) 2001-11-08
IT1291372B1 (it) 1999-01-07
WO1998052568A1 (en) 1998-11-26
ITMI971190A1 (it) 1998-11-21
EP0983068B1 (en) 2001-11-28
CA2289847A1 (en) 1998-11-26
ATE209492T1 (de) 2001-12-15
DE69802679D1 (de) 2002-01-10
AU7654698A (en) 1998-12-11
EP0983068A1 (en) 2000-03-08
CN1255854A (zh) 2000-06-07

Similar Documents

Publication Publication Date Title
EP0983068B1 (en) THE USE OF 1,2,4-TRIAZOLO 1,5-c]PYRIMIDINE HETEROCYCLIC ANALOGUES FOR THE PREPARATION OF MEDICAMENTS USEFUL FOR THE TREATMENT OF CEREBROVASCULAR DISTURBANCES
JP4248239B2 (ja) プリン作用性レセプターアンタゴニストとしてのピロロ[2,3−d]ピリミジンおよびそれらの使用
KR100687954B1 (ko) 아데노신 A2a 수용체 길항제로서의이미다조(4,3-e)-1,2,4-트리아졸로(1,5-c) 피리미딘
AU715380B2 (en) Pyrazolopyrimidines for treatment of neuronal and other disorders
DE69611377T2 (de) 1,2,4-triazolo[1,5-c]pyrimidin-heterocyclische analoge mit antagonistischer aktivität auf dem adenosine a2a rezeptor
JP2021534259A (ja) JAK阻害剤としての[1,2,4]トリアゾロ[1,5−a]ピリジン化合物およびその使用
TW200914048A (en) Combinations for the treatment of B-cell proliferative disorders
KR20080107416A (ko) A2b 아데노신 수용체 길항제를 사용하는 간질환의 예방 및 치료 방법
AU2002340184A1 (en) Imidazo (4,3-E)-1,2,4-triazolo(1,5-C) pyrimidines as adenosine A2A receptor antagonists
EP0623133B1 (en) Substituted amino alkyl compounds
JP2015536973A (ja) PDE4阻害剤とPI3δ阻害剤または二重PI3δ−γキナーゼ阻害剤とを含有する薬学的組成物
JP2001504130A (ja) キサンチン類およびこれらの治療的使用
WO2000017201A1 (en) [1,2,4]TRIAZOLO[1,5-c]PYRIMIDINE DERIVATIVES
JP2022501344A (ja) 新規キナゾリンegfr阻害剤
JP2002508315A (ja) 性的不能の治療に有効な組合せ
US20200172529A1 (en) Chemical Compound, Pharmaceutical Composition Thereof, and Use and Application Thereof
JP2001526637A (ja) マラリアの処置のための(+)メフロキンの使用
KR20090042330A (ko) 혈액뇌장벽을 통과하지 않는 kw―3902 컨쥬게이트
JP2002543133A (ja) ロフルミラストおよびpde−3インヒビターを含有する共力薬の組合せ物
CA2433409C (en) Use of mglur5 antagonists for the treatment of pruritic conditions
CN108367016A (zh) 用于治疗异位脂肪堆积的a3腺苷受体配体
JP2026515688A (ja) Aak1阻害剤としての窒素複素環系化合物
WO2010053127A1 (ja) α1GABAA受容体またはα5GABAA受容体の調整剤
EP1425011B1 (en) Enhancement of learning and memory and treatment of amnesia
KR20070008689A (ko) 아데노신 a1 수용체 길항제 및 알도스테론 억제제를포함하는 병용 요법